Advertisement

Medikamentöse Behandlung des Uterus myomatosus

  • J. F. H. Gauwerky
  • D. Djavadian

Zusammenfassung

Die endokrine Behandlung des Uterus myomatosus ist naheliegend. Myome entstehen in der fertilen Phase der Frau unter Hormoneinfluss und verlieren häufig an Bedeutung in der Menopause. Eine ganze Reihe von endokrinen Ansatzpunkten ist denkbar (s. Übersicht). GnRH-Analoga wurden lange Zeit in der endokrinen Behandlung favorisiert. Sie gehörten zu »multimodalen« Therapiekonzepten. Eine Vorbehandlung vor operativer Intervention war fast obligat. Heute wird ihre Bedeutung jedoch nicht mehr so wertig gesehen. Im Folgenden soll das Spektrum der medikamentösen Behandlungsmöglichkeiten des Uterus myomatosus kompakt dargestellt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Benagiano G, Kivinen ST, Fadini R, Cronje H, Klintorp S, van der Spuy ZM (1996) Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Fertil Steril 66(2): 223–229PubMedGoogle Scholar
  2. Bianchi S, Fedele L, Vignali M, Galbiati E, Cherubini R, Ortolani S (1995) Effects an bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas. Calcif Tissue Int 57(1): 78–80PubMedCrossRefGoogle Scholar
  3. Branham WS, Fishman R, Streck RD, Medlock KL, De George JJ, Sheehan DM (1996) ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity. Biol Reprod 54(1): 160–167PubMedCrossRefGoogle Scholar
  4. Brosens I, Deprest J, Dal Cin P, Van den Berghe H (1998) Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril 69(2): 232–235PubMedCrossRefGoogle Scholar
  5. Burroughs KD, Kiguchi K, Howe SR, Fuchs-Young R, Trono D, Barrett JC, Walker C (1997) Regulation of apoptosis in uterine leiomyomata. Endocrinology 138(7): 3056–3064PubMedCrossRefGoogle Scholar
  6. Coutinho EM, Goncalves MT (1989) Long-term treatment of leiomyomas with gestrinone. Fertil Steril 51(6): 939–946PubMedGoogle Scholar
  7. Demopoulos RI, Jones KY, Mittal KR, Vamvakas EC (1997) Histology of leiomyomata in patients treated with leuprolide acetate. Int J Gynecol Pathol 16(2): 131–137PubMedCrossRefGoogle Scholar
  8. Dilts PV Jr, Hopkins MP, Chang AE, Cody RL (1992) Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol 166: 167–168PubMedGoogle Scholar
  9. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C (1996) A controlled trial of raloxifene (LY139481) HCI: impact an bone turnover and serum lipid profìle in healthy postmenopausal women. J Bone Miner Res 11(6): 835–842PubMedCrossRefGoogle Scholar
  10. Dukes M, Waterton JC, Wakeling AE (1993) Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 138(2): 203–210PubMedCrossRefGoogle Scholar
  11. Felberbaum RE, Germer U, Ludwig M et al. (1998) Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 13(6): 1660–1668PubMedCrossRefGoogle Scholar
  12. Fruscella L, Ciaglia EM, Danti M, Fiumara D (1997) Vitamin E in the treatment of pregnancy complicated by uterine myoma. Minerva Ginecol 49(4): 175–179PubMedGoogle Scholar
  13. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C (1996) Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 17(3): 151–159PubMedCrossRefGoogle Scholar
  14. Gerris J, Degueldre M, Peters AA, Romao F, Stjernquist M, al-Taher H (1996) The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group. Horm Res 45(6): 279–284PubMedCrossRefGoogle Scholar
  15. Gonzalez-Barcena D, Alvarez RB, Ochoa EP et al. (1997) Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 12(9): 2028–2035PubMedCrossRefGoogle Scholar
  16. Hackenberg R, Gesenhues T, Deichert U, Duda V, Schmidt-Rhode P, Schulz KD (1992) The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month. Eur J Obstet Gynecol Reprod Biol 45(2): 125–129PubMedCrossRefGoogle Scholar
  17. Harrison-Woolrych ML, Chamock-Jones DS, Smith SK (1994) Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 78(5): 1179–1184PubMedCrossRefGoogle Scholar
  18. Healy DL, Burger HG (1977) Review: human prolactin-recent advances in physiology and therapy. Aust N Z J Obstet Gynaecol 17(2): 61–78PubMedCrossRefGoogle Scholar
  19. Howe SR, Gottardis MM, Everitt JI, Walker C (1995) Estrogen Stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 136(11): 4996–5003PubMedCrossRefGoogle Scholar
  20. Kedar RP, Boume TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S (1994) Effects of tamoxifen an uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343(8909): 1318–1321PubMedCrossRefGoogle Scholar
  21. Le Bouedec G, de Latour M, Dauplat J (1995) Expansive uterine myoma during tamoxifen therapy. 11 cases. Presse Med 24(36): 1694–1696PubMedGoogle Scholar
  22. Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 92(20): 9220–9224PubMedCrossRefGoogle Scholar
  23. Lumsden MA, West CP, Hillier H, Baird DT (1989) Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)-lack of shrinkage of uterine fibroids. Fertil Steril 52(6): 924–929PubMedGoogle Scholar
  24. Mettler L, Mayer-Eichenberger D, Kienle E, Lipka K (1993) Leuprorelinacetat-Depot zur Behandlung des Uterus myomatosus. Fertilität 9: 167–174Google Scholar
  25. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS (1993) Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 76(2): 513–517PubMedCrossRefGoogle Scholar
  26. O’Reilly MS (1997) Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79: 273–294PubMedGoogle Scholar
  27. Rutgers JL, Spong CY, Sinow R, Heiner J (1995) Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol 86(3): 386–388PubMedCrossRefGoogle Scholar
  28. Sadan O, van Iddekinge B, van Gelderen CJ, Savage N, Becker PJ, van der Walt LA, Robinson M (1987) Oestrogen and progesterone reeeptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 24: 263–267PubMedGoogle Scholar
  29. Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA (1989) A placebo-controlled trial of a depot gonadotropinreleasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol. 74(6): 856–862PubMedGoogle Scholar
  30. Sun L (1995) 38 cases of hysteromyoma treated with tumor-resolving decoction. J Tradit Chin Med 15(4): 273–276PubMedGoogle Scholar
  31. Surrey ES (1995) Steroidal and nonsteroidal »add-back« Therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynaecologic patient. Fertil Steril 64(4): 673–685PubMedGoogle Scholar
  32. Stolz W, Pfutzenreuter N (1997) Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect an leiomyoma volume and operability. German Leuprorelin Study Group. Zentralbl Gynakol 119(10): 468–475PubMedGoogle Scholar
  33. Thomas EJ, Walton PL, Thomas NM, Dowsett M (1994) The effect of ICI 182,780, a pure antioestrogen, an the hypothalamic-pituitary-gonadal axis and an endometrial proliferation in premenopausal women. Hum Reprod 9(11): 1991–1996PubMedGoogle Scholar
  34. Ueki M, Okamoto Y, Tsurunaga T, Seiki Y, Ueda M, Sugimoto O (1995) Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. J Obstet Gynaecol 21(1): 1–7Google Scholar
  35. Wade GN, Powers JB, Blaustein JD, Green DE (1993) ICI 182,780 antagonizes the effects of estradiol an estrous behavior and energy balance in Syrian hamsters. Am J Physiol 265: R1399–1403PubMedGoogle Scholar
  36. Wakeling AE, Bowler J (1992) ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43(1–3): 173–177PubMedCrossRefGoogle Scholar
  37. Yan H, Wang J (1994) The clinical study an hysteromyoma treated with acupuncture. Zhen Ci Yan Jiu 19: 14–16PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • J. F. H. Gauwerky
  • D. Djavadian

There are no affiliations available

Personalised recommendations